San Francisco Patient Fight Back Lou Gehrig’s Disease Tenaciously

by Gopalan on  March 23, 2008 at 12:03 PM General Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

San Francisco Patient Fight Back Lou Gehrig’s Disease Tenaciously
Lou Gherig's might be a terribly wasting disease, with no cure available until now. But a celebrated patient, Dr. Richard Olney of San Francisco, is fighting back tenaciously.

The 57-year-old California neurologist's self-diagnosis back in 2004 had made international headlines.

Ironically he had founded the ALS Treatment and Research Center the University of California, San Francisco (UCSF). Over his 29-year career, he had diagnosed amyotrophic lateral sclerosis (ALS) in more than 1,000 patients.

But on June 11, 2004, Dr. Olney learned that he himself had ALS, (popularly known as Lou Gherig's disease) and was about to become a patient at the center he founded.

ALS is slowly killing him. Still he has miraculously survived thus far, defying all dire predictions.

Of unknown origin, the disease is marked by the destruction of motor neurons, the nerve cells that trigger and control muscle movement. It is a progressive and invariably fatal illness. Patients are fully alert to the end. They retain the sense of touch and mercifully experience no abnormal pain, but within two to four years, most patients are unable to move, swallow or breathe.

Olney's illness began as a weakness in his right knee. Then he lost the ability to walk, to move his arms or legs and then to speak. Doctors thought he had only months to live. But after ALS robbed him of all muscle movement but a slight ability to nod his head, the disease mysteriously stabilized. His condition has remained unchanged for a year and a half.

"I think I have an unusual variant of ALS," Olney told a visitor to his home.

His words were not spoken, but spelled out on a large white placard - a handmade communication system that works like a Ouija board. Laid out across his lap are the letters of the alphabet; the numbers zero to 9; the answers "yes" and "no;" often-used words such as "can," "can't," "feel," "lift" and "want;" and the names of his wife, Paula, his son, Nick, and daughter, Amy.

Olney spells out his thoughts readily, rapidly, using a laser pointer mounted on a pair of eyeglass frames.

His wife, a kidney dialysis nurse who has been married to him for 33 years, is grateful for the reprieve. "We've quit thinking in terms of his dying," she said.

"I have not," Olney quickly spelled out, a mischievous twinkle in his eye.

Although the cause of ALS is as mysterious today as it was the 1800s, when the disease was first identified, about 5 to 10 percent of cases are inherited. So families that have experienced the illness are best prepared to deal with it.

Olney's case was not inherited. No one else in his family has suffered from it. He stressed that his illness was not contracted from caring for patients. ALS is not contagious, but it is surprisingly common. About 1 in every 1,000 Americans - more men than women - will develop it in their lifetime. That puts it on a par with better known diseases, such as multiple sclerosis. Yet because ALS is so rapidly fatal, the number of patients living with the disease at any given time - about 30,000 in the United States - is one tenth the number with multiple sclerosis.

About 10 percent of ALS patients can live 10 years or longer without needing a ventilator. Olney is realistic that chances are slim he will be one of them. He was diagnosed at the age of 55. Now he is 60. "There are exceptions, but generally the younger you are diagnosed, the longer you live," he said.

Olney has formally rejected use of a ventilator. When his breathing fails, he will die, writes Sabin Russell in San Francisco Chronicle.

Only one drug is approved to treat ALS, and in January 2005 Olney was first to sign up for a clinical trial he had designed prior to his illness. It would test whether an AIDS drug, ritonavir, might slow the disease. Olney did not know during the trial whether he was given the real drug, or a placebo, or another medication, hydroxyurea. Both the active drugs - already approved for entirely different uses - were thought to interfere with processes involved in the destruction of nerve cells in ALS patients.

After six months, however, the ritonavir experiment was halted when preliminary data showed that the ALS patients who received that drug might be faring worse. It turned out that Olney was one of them.

While Olney cannot work in his old lab, he keeps up with the literature in the field of ALS research, and he continues to publish. In January, the Journal of Life Sciences published his latest article: "When the Doctor Becomes the Patient."

"I became anxious a few times when thinking about how disabled I would become," he wrote - using a modified computer mouse and specialized software. "My anxiety was relieved when I followed my own advice. I focused on what I was able to do today and realized that more disability would come on gradually, meaning that I would have time to adjust to it."

Olney has a close-knit and caring family, which surrounds him with love and support. He said he is relieved that he has had time to prepare them for a future when he is no longer there. "Prepare for the worst, but hope for the best," he said.

Paula Olney at times is visibly pained by the horrible turn of events. Also, home health care is very expensive, but she feels fortunate that a long-term care insurance policy covers about half the $5,000 a month required. She and their two children continue to be inspired by her husband's tenacity. "He is living out of sheer will," she said.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive